




Appendix

	N	Mean	Percent
Postmenopausal women	86/121		71.10%
Anti-cholinergic use	28/112		25%
Physiotherapy	35/113		31%
Estrogen treatment	57/114		50%
BMI		27.51	
Underweight (BMI <20)	9/96	9.4	
Normal (BMI 20-25)	34/96	35.4	
Overweight (BMI 25-30)	27/96	28.1	
Obese (BMI >30)	26/96	27.1	

Table 1: Patient Characteristics.






Figure 2: Changes in bladder function in women who underwent FxCO₂ and PRP.




Figure 3: Mean bladder function symptom severity at each timeframe

	APFQ	Change between T1-T2							
		Improvement %	n	z	r	P value <0/05	Mean	± STD	Median
Frequency	1	70.67	85	-4.085	0.31	0	T1 = 0.74	± 0.772	T1=1
							T2 = 0.36	± 0.644	T2 =0
Nocturia	2	51.9	89	-2.333	0.17	0.02	T1 = 0.65	± 0.956	T1=0
							T2 = 0.47	± 0.709	T2=0
Enuresis	3	60.71	89	-1.833	0.14	0.067	T1 = 0.23	± 0.539	T1=0
							T2 = 0.09	± 0.358	T2 =0
Urgency	4	67.34	88	-6.95	0.52	0	T1 = 2.40	± 0.733	T1=3
							T2 = 1.17	± 0.895	T2=1
Urge	5	80.9	89	-7.64	0.57	0	T1 = 2.31	±0.466	T1=2
							T2 = 0.97	± 0.775	T2 =1
Incontinence Stress	6	68.42	88	-6.013	0.45	0	T1 =1.61	± 1.143	T1=2
							T2 = 0.74	± 0.886	T2=1
Incontinence Flow	7	75.58	85	-5.171	0.4	0	T1 = 1.41	±1.126	T1=1
							T2 = 0.57	± 0.848	T2=0
Retention	8	72.11	87	-4.753	0.36	0	T1 = 1.39	± 1.103	T1=1
							T2 = 0.66	± 0.852	T2=0
Urinary	9	73.11	95	-5.255	0.38	0	T1 = 1.21	±1.146	T1=1
							T2 = 0.54	± 0.830	T2=0
straining Pads	10	59.19	87	-4.394	0.33	0	T1 = 1.48	± 1.298	T1=1
							T2 = 0.82	± 0.989	T2=1
Limit intake	11	63.86	81	-3.893	0.31	0	T1 = 0.89	± 0.994	T1=1
							T2 = 0.49	± 0.745	T2=0
Recurrent UTI	12	91.67	82	-3.157	0.25	0.002	T1 = 0.48	± 0.833	T1=0
							T2 = 0.22	± 0.441	T2 =0
Dysuria	13	84.25	82	-4.653	0.36	0	T1 = 0.84	± 0.838	T1=0
							T2 = 0.15	± 0.418	T2 =0
Activities	14	73.91	82	-5.886	0.46	0	T1 = 1.53	± 1.083	T1=1
							T2 = 0.67	± 0.787	T2=1
How bothersome (QoL)	15	57.37	81	-6.28	0.49	0	T1 = 2.19	± 0.891	T1=2
							T2 = 1.24	± 0.902	T2=1
Prolapse	28	56.62	71	-3.305	0.28	0.001	T1 = 0.89	± 1.149	T1=0
							T2 = 0.62	± 0.968	T2=0
GSM	39	60.63	55	-2.797	0.27	0.005	T1 = 1.09	± 1.085	T1=1
							T2 = 0.68	± 0.805	T2=1
Bladder function	Scale	88.27	71	-6.427	0.54	0	T1 = 2.25	± 0.713	T1=2
							T2 = 1.33	± 0.543	T2=1

Table 2: Outcomes for women who underwent FxCO₂ and PRP at T1 compared to T2. Changes are represented using Wilcoxon's signed-rank test scores.

	APFQ	Change between T1-T3							
		Improvement %	n	z	r	P value <0/05	Mean	± STD	Median
Frequency	1	85.33	45	-3.622	0.38	0	T1 = 0.74	± 0.772	T1=1
							T3= 0.3	± 0.511	T3= 0
Nocturia	2	79.52	46	-2.045	0.21	0.041	T1 = 0.65	± 0.956	T1=0
							T3= 0.41	± 0.580	T3= 0
Enuresis	3	100	46	-0.535	0.06	0.593	T1 = 0.23	± 0.539	T1=0
							T3= 0.17	± 0.383	T3= 0
Urgency	4	53.8	46	-4.921	0.51	0	T1 = 2.40	± 0.733	T1=3
							T3= 1.33	± 0.871	T3= 1
Urge	5	67.3	58	-5.505	0.51	0	T1 = 2.31	±0.466	T1=2
							T3= 1.12	± 0.938	T3= 1
Incontinence Stress	6	65.79	46	-3.929	0.41	0	T1=1.61	± 1.143	T1=2
							T3= 0.85	± 0.894	T3= 1
Incontinence Flow	7	57.05	49	-2.847	0.29	0.004	T1 = 1.41	±1.126	T1=1
							T3= 0.69	± 0.895	T3= 0
Retention	8	69.83	48	-3.362	0.34	0.001	T1 = 1.39	± 1.103	T1=1
							T3= 0.65	± 0.838	T3= 0
Urinary	9	84.91	47	-3.815	0.39	0	T1 = 1.21	±1.146	T1=1
							T3= 0.32	± 0.594	T3= 0
straining Pads	10	65.92	46	-3.463	0.36	0.001	T1 = 1.48	± 1.298	T1=1
							T3= 0.72	± 1.026	T3= 0
Limit intake	11	61.75	43	-2.81	0.3	0.005	T1 = 0.89	± 0.994	T1=1
							T3= 0.41	± 0.748	T3= 0
Recurrent UTI	12	50.76	43	-2.296	0.25	0.022	T1=0.48	± 0.833	T1=0
							T3= 0.3	± 0.591	T3= 0
Dysuria	13	84.93	43	-3.566	0.38	0	T1 = 0.84	± 0.838	T1=0
							T3= 0.15	± 0.420	T3= 0
Activities	14	68.53	43	-4.3	0.46	0	T1 = 1.53	± 1.083	T1=1
							T3= 0.63	± 0.853	T3= 0
How bothersome (QoL)	15	59.6	41	-4.607	0.51	0	T1 = 2.19	± 0.891	T1=2
							T3= 1.04	± 1.074	T3= 1
Prolapse	28	39.74	37	-3.816	0.44	0	T1 = 0.89	± 1.149	T1=0
							T3= 0.61	± 0.945	T3= 0
GSM	39	51.92	23	-2.913	0.43	0.004	T1 = 1.09	± 1.085	T1=1
							T3= 0.55	± 0.736	T3= 0
Bladder function	Scale	85.67	40	-5.245	0.59	0	T1 = 2.25	± 0.713	T1=2
							T3= 1.29	± 0.549	T3= 1

Table 3: Outcomes for women who underwent FxCO₂ and PRP at pre-treatment (T1) compared to 12-24 months after treatment (T3). Changes are represented using Wilcoxon's signed-rank test scores.

